Cargando…

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients

BACKGROUND: Mutated circulating cell-free DNA (cfDNA) has been suggested as a surrogate marker of tumour burden and aggressiveness of disease. We examined the association between the level of plasma mutant cfDNA and metabolic tumour burden (MTB) measured by (18)F-fluoro-D-glucose positron emission t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winther-Larsen, Anne, Demuth, Christina, Fledelius, Joan, Madsen, Anne Tranberg, Hjorthaug, Karin, Meldgaard, Peter, Sorensen, Boe Sandahl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572172/ https://www.ncbi.nlm.nih.gov/pubmed/28683468 http://dx.doi.org/10.1038/bjc.2017.215

Ejemplares similares

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
por: Demuth, Christina, et al.
Publicado: (2018)

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
por: Madsen, Anne Tranberg, et al.
Publicado: (2020)

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
por: Winther-Larsen, Anne, et al.
Publicado: (2016)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Day-to-day and within-day biological variation of cell-free DNA
por: Madsen, Anne Tranberg, et al.
Publicado: (2019)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
por: Greystoke, A, et al.
Publicado: (2012)

Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours
por: Childs, Alexa, et al.
Publicado: (2016)

Neurofilament Light Chain as A Biomarker for Brain Metastases
por: Winther-Larsen, Anne, et al.
Publicado: (2020)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Intra‐individual variation of circulating tumour DNA in lung cancer patients
por: Hojbjerg, Johanne A., et al.
Publicado: (2019)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation
por: Skvortsova, T E, et al.
Publicado: (2006)

Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope
por: Ntouroupi, T G, et al.
Publicado: (2008)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients
por: Wong, S C C, et al.
Publicado: (2011)

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
por: Hadano, Naoto, et al.
Publicado: (2016)

Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma
por: Hamana, K, et al.
Publicado: (2005)

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
por: Khoja, L, et al.
Publicado: (2012)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation
por: Sadanandam, A, et al.
Publicado: (2012)

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
por: Nygaard, A D, et al.
Publicado: (2014)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
por: Weidlich, S, et al.
Publicado: (2011)

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
por: Benoy, I H, et al.
Publicado: (2006)

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
por: Molloy, T J, et al.
Publicado: (2011)

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
por: Flores, L M, et al.
Publicado: (2010)

The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy
por: Payne, R E, et al.
Publicado: (2012)

Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment
por: Nel, I, et al.
Publicado: (2013)

Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer
por: Guthrie, G J K, et al.
Publicado: (2013)

Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer
por: Ueo, H, et al.
Publicado: (2015)

Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients
por: Payne, R E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uodcm7u0mug2pf7a81lu1ulsh0